Nurix Therapeutics(NRIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRIX Nurix Therapeutics

Pre-Mkt 05-20 07:55:12 EDT

15.24

-0.27

-1.74%

盘前15.10

-0.14-0.92%

04:27 EDT

High15.67	Low15.07	Vol1.06M
Open15.34	D1 Closing15.51	Amplitude3.87%
Mkt Cap1.58B	Tradable Cap1.32B	Total Shares103.41M
T/O16.21M	T/O Rate1.23%	Tradable Shares86.36M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NRIX","market":"US","secType":"STK","nameCN":"Nurix Therapeutics","latestPrice":15.24,"timestamp":1779220800000,"preClose":15.51,"halted":0,"volume":1060387,"hourTrading":{"tag":"盘前","latestPrice":15.1,"preClose":15.24,"latestTime":"04:27 EDT","volume":27,"amount":405.620028,"timestamp":1779265624493,"change":-0.14,"changeRate":-0.009186,"amplitude":0.031496},"delay":0,"changeRate":-0.017408123791102487,"floatShares":86361800,"shares":103405813,"eps":-3.165026,"marketStatus":"Pre-Mkt","change":-0.27,"latestTime":"05-20 07:55:12 EDT","open":15.34,"high":15.67,"low":15.07,"amount":16207493.584596,"amplitude":0.038685,"askPrice":17.03,"askSize":100,"bidPrice":13.95,"bidSize":18,"shortable":3,"etf":0,"ttmEps":-3.165026,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1779283800000},"marketStatusCode":1,"adr":0,"listingDate":1595563200000,"exchange":"NASDAQ","adjPreClose":15.24,"preHourTrading":{"tag":"盘前","latestPrice":15.1,"preClose":15.24,"latestTime":"04:27 EDT","volume":27,"amount":405.620028,"timestamp":1779265624493,"change":-0.14,"changeRate":-0.009186,"amplitude":0.031496},"postHourTrading":{"tag":"盘后","latestPrice":15.69,"preClose":15.24,"latestTime":"18:33 EDT","volume":32400,"amount":494158.7853,"timestamp":1779230030827,"change":0.45,"changeRate":0.029528,"amplitude":0.045932},"volumeRatio":0.988720393334662,"impliedVol":0.37,"impliedVolPercentile":0.064},"requestUrl":"/m/hq/s/NRIX/wiki","defaultTab":"wiki","newsList":[{"id":"2636102298","title":"Nurix Therapeutics Price Target Maintained With a $30.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2636102298","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636102298?lang=en_us&edition=fundamental","pubTime":"2026-05-18 18:35","pubTimestamp":1779100500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRIX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 18, 2026 06:35 ET (10:35 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635053891","title":"Nurix Therapeutics Shareholders Back Directors and Governance Proposals","url":"https://stock-news.laohu8.com/highlight/detail?id=2635053891","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635053891?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:11","pubTimestamp":1778879494,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Nurix Therapeutics ( ($NRIX) ). On May 15, 2026, Nurix Therapeutics, Inc. held its 2026 Annual Meeting of Stock...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nurix-therapeutics-shareholders-back-directors-and-governance-proposals?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nurix-therapeutics-shareholders-back-directors-and-governance-proposals?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635803799","title":"Nurix Therapeutics shareholders ratify PwC as auditor for fiscal 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635803799","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635803799?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:07","pubTimestamp":1778875637,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics held its annual shareholder meeting on May 15, 2026.Votes also backed appointment of three directors to new terms running through 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nurix Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 15, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL3TWRZW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635725906","title":"Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2635725906","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635725906?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:05","pubTimestamp":1778789100,"startTime":"0","endTime":"0","summary":"In preclinical studies of CSU, Bexobrutideg demonstrates potent BTK degradation across key immune cell types and enhanced suppression of FcεRI-driven pathology versus remibrutinib In healthy volunteer","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3295365/0/en/Nurix-Therapeutics-Presents-New-Preclinical-and-Phase-1-Translational-Data-Supporting-Bexobrutideg-NX-5948-in-Chronic-Spontaneous-Urticaria-at-the-2026-Society-for-Investigative-De.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4086","LU2065732104.USD","BK4139","NRIX","NX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635058784","title":"Nurix Therapeutics (NRIX) Receives a Buy from Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2635058784","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635058784?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:18","pubTimestamp":1778674694,"startTime":"0","endTime":"0","summary":"In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Nurix Therapeutics, with a price target of $28.00. Accordin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/nurix-therapeutics-nrix-receives-a-buy-from-oppenheimer-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/nurix-therapeutics-nrix-receives-a-buy-from-oppenheimer-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OPY","NRIX","BK4127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635578150","title":"Piper Sandler Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635578150","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635578150?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:38","pubTimestamp":1778672298,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Biren Amin maintained a Buy rating on Nurix Therapeutics today and set a price target of $35.00. According to TipRanks, Amin ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-nurix-therapeutics-nrix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-nurix-therapeutics-nrix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635108786","title":"Nurix CEO Sands to join RBC Global Healthcare Conference fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2635108786","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635108786?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:07","pubTimestamp":1778670422,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics CEO Arthur T. Sands will join a fireside chat at RBC Global Healthcare Conference on May 20, 2026, at 1:30 p.m. ET.He is also scheduled for a fireside chat at Jefferies Global Healthcare Conference on June 3, 2026, at 11:05 a.m. ET.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDLcg7prx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","SG9999014021.USD","BK4585","LU2095319765.USD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","SG9999014013.SGD","IE00BN0W2V16.EUR","SG9999014005.SGD","IE00BN0W2T93.GBP","NDAQ","SG9999014039.USD","BK4139","LU0314104364.USD","IE00BKPKM429.USD","BK4588","IE00B3QW5Z07.USD","NRIX","LU2210150020.SGD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635869167","title":"Nurix Therapeutics to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2635869167","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635869167?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:00","pubTimestamp":1778670000,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., May  13, 2026  (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293827/0/en/Nurix-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635223582","title":"BRIEF-Nurix Therapeutics Announces Bexobrutideg Oral Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2635223582","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635223582?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:06","pubTimestamp":1778619962,"startTime":"0","endTime":"0","summary":"BRIEF-Nurix Therapeutics Announces Bexobrutideg Oral Presentation May 12 (Reuters) - Nurix Therapeutics Inc NRIX.O:NURIX THERAPEUTICS ANNOUNCES BEXOBRUTIDEG ORAL PRESENTATION AT THE 2026 EUROPEAN HEMA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA64ZKZF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635247132","title":"Nurix to present updated Phase 1 data for BTK degrader bexobrutideg in CLL at EHA2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635247132","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635247132?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:09","pubTimestamp":1778616579,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics flagged updated efficacy and safety findings for BTK degrader bexobrutideg  from an ongoing Phase 1a/b study in chronic lymphocytic leukemia, accepted for an oral presentation at EHA2026.Results have not yet been presented; disclosure is scheduled for June 14, 2026, in Stockholm during a relapsed or refractory CLL session.Company positioned the update as covering performance and tolerability across treatment lines, supporting continued development in CLL.Bexobrutideg remains in clinical testing, with a pivotal single-arm Phase 2 study in relapsed or refractory CLL running alongside broader Phase 1 enrollment in B-cell malignancies.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL8trtyf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","LU2210149790.SGD","LU2210150020.SGD","LU2095319765.USD","IE00B3QW5Z07.USD","NDAQ","SG9999014039.USD","BK4588","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","SG9999014021.USD","SG9999014005.SGD","IE00BKPKM429.USD","LU0314104364.USD","SG9999014013.SGD","NRIX","BK4112","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635247312","title":"Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2635247312","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635247312?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616304,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA64ZKZF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633797562","title":"Nurix CFO Hans van Houte disposes of common shares worth $233,463.29","url":"https://stock-news.laohu8.com/highlight/detail?id=2633797562","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633797562?lang=en_us&edition=fundamental","pubTime":"2026-05-06 07:54","pubTimestamp":1778025261,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics CFO Hans van Houte sold 14,055 shares of common stock on May 5, 2026.Sales priced at USD 16.58 per share for 13,473 shares, USD 17.18 per share for 582 shares.Directly held stake fell to 37,592 shares following transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nurix Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL4vkjss:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nurix CFO Hans van Houte disposes of common shares worth $233,463.29","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633964285","title":"Nurix Chief Legal Officer Christine Ring disposes 8,148 shares worth $138,205","url":"https://stock-news.laohu8.com/highlight/detail?id=2633964285","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633964285?lang=en_us&edition=fundamental","pubTime":"2026-05-05 06:11","pubTimestamp":1777932681,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics Chief Legal Officer Christine Ring sold 8,148 shares of common stock on May 4, 2026.Sale priced at weighted average USD 16.96 per share.Directly held stake fell to 18,305 shares following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nurix Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 04, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL9L2HPl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nurix Chief Legal Officer Christine Ring disposes 8,148 shares worth $138,205","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632512674","title":"Is Nurix’s Pan-Mutant BRAF Degrader Data Reshaping The Investment Case For Nurix Therapeutics (NRIX)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2632512674","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632512674?lang=en_us&edition=fundamental","pubTime":"2026-05-03 01:38","pubTimestamp":1777743516,"startTime":"0","endTime":"0","summary":"At the April 2026 AACR Annual Meeting, Nurix Therapeutics reported new preclinical and early clinical data showing progress across its targeted protein degradation oncology pipeline, including programs aimed at pan-mutant BRAF, CBL-B, and Aurora kinase A.\nBeyond individual drug candidates, the presentations underscored how Nurix’s induced proximity and protein degradation platforms may overcome resistance and pathway limitations that challenge traditional cancer therapies.\nWith this context...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/is-nurixs-pan-mutant-braf-degrader-data-reshaping-the-invest","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/is-nurixs-pan-mutant-braf-degrader-data-reshaping-the-invest","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632854623","title":"Nurix Chief Legal Officer Christine Ring sells 5,394 shares for $90,435","url":"https://stock-news.laohu8.com/highlight/detail?id=2632854623","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632854623?lang=en_us&edition=fundamental","pubTime":"2026-05-02 05:51","pubTimestamp":1777672275,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics Chief Legal Officer Christine Ring sold 5,394 shares on May 1, 2026.Sale priced at USD 16.76 per share on weighted-average basis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nurix Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL3d2N5f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nurix Chief Legal Officer Christine Ring sells 5,394 shares for $90,435","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630396342","title":"Nurix Therapeutics Price Target Maintained With a $32.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2630396342","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630396342?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:59","pubTimestamp":1777291140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRIX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 27, 2026 07:59 ET (11:59 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629538836","title":"Nurix Therapeutics (NRIX) Receives a Buy from Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2629538836","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629538836?lang=en_us&edition=fundamental","pubTime":"2026-04-23 19:41","pubTimestamp":1776944469,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Biren Amin maintained a Buy rating on Nurix Therapeutics today and set a price target of $35.00. According to TipRanks, Amin ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/nurix-therapeutics-nrix-receives-a-buy-from-piper-sandler-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/nurix-therapeutics-nrix-receives-a-buy-from-piper-sandler-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629835520","title":"Nurix Therapeutics Price Target Maintained With a $26.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2629835520","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629835520?lang=en_us&edition=fundamental","pubTime":"2026-04-23 19:21","pubTimestamp":1776943260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRIX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 23, 2026 07:21 ET (11:21 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629048932","title":"Nurix reports early clinical NX-1607 target engagement data at AACR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629048932","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629048932?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:07","pubTimestamp":1776856061,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics released new preclinical oncology data at AACR 2026, with results already presented in posters and an oral session.NRX-0305 showed strong anti-tumor activity in brain cancer models, including in settings resistant to existing BRAF drugs.NX-1607 demonstrated immune-activating effects in preclinical studies, with early clinical findings indicating target engagement in patients.NRX-4972 delivered better tumor control than AURKA inhibitors in an aggressive small cell lung cancer model, supporting continued development of Nurix’s degrader approach.Gwenn Hansen is scheduled to present an AACR Advances session talk later today on lessons from early clinical experience with degrader therapeutics.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDLbq1Zb8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","NDAQ","NRIX","BK4585","SG9999014005.SGD","IE00BGHQF748.EUR","LU2095319765.USD","BK4139","IE00B3QW5Z07.USD","SG9999014021.USD","LU0314104364.USD","BK4588","LU2210150020.SGD","BK4112","SG9999014013.SGD","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629830048","title":"Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629830048","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629830048?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:00","pubTimestamp":1776855600,"startTime":"0","endTime":"0","summary":"Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programs Presentations reinforce potential of degraders to overcome limitations of inhibitors and expand ther","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/22/3278794/0/en/Nurix-Therapeutics-Announces-New-Preclinical-Data-Highlighting-Breadth-of-Targeted-Protein-Degradation-Pipeline-at-AACR-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","NRIX","PDX","BK4139","CNS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nurixtx.com","stockEarnings":[{"period":"1week","weight":-0.0451},{"period":"1month","weight":-0.1296},{"period":"3month","weight":-0.0155},{"period":"6month","weight":-0.0059},{"period":"1year","weight":0.6025},{"period":"ytd","weight":-0.1966}],"compareEarnings":[{"period":"1week","weight":-0.006},{"period":"1month","weight":0.0332},{"period":"3month","weight":0.0691},{"period":"6month","weight":0.1244},{"period":"1year","weight":0.2335},{"period":"ytd","weight":0.076}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing DeTIL-0255, a drug-enhanced investigational cell therapy product that uses NX-0255 ex vivo to enhance tumor infiltrating lymphocytes propagation and phenotypic characteristics. The company has a strategic collaboration agreement with Gilead Sciences, Inc. to discover, develop, and commercialize a pipeline of protein degradation drugs for patients with cancer and other challenging diseases; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074756},{"month":2,"riseRate":0.166667,"avgChangeRate":-0.011931},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.064842},{"month":4,"riseRate":0.5,"avgChangeRate":-0.023295},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.015258},{"month":6,"riseRate":0.6,"avgChangeRate":0.118065},{"month":7,"riseRate":0.6,"avgChangeRate":0.085462},{"month":8,"riseRate":0.5,"avgChangeRate":0.016029},{"month":9,"riseRate":0.166667,"avgChangeRate":0.009437},{"month":10,"riseRate":0.5,"avgChangeRate":0.003905},{"month":11,"riseRate":0.5,"avgChangeRate":0.149774},{"month":12,"riseRate":0.5,"avgChangeRate":0.041068}],"exchange":"NASDAQ","name":"Nurix Therapeutics","nameEN":"Nurix Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nurix Therapeutics(NRIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nurix Therapeutics(NRIX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nurix Therapeutics,NRIX,Nurix Therapeutics股票,Nurix Therapeutics股票老虎,Nurix Therapeutics股票老虎国际,Nurix Therapeutics行情,Nurix Therapeutics股票行情,Nurix Therapeutics股价,Nurix Therapeutics股市,Nurix Therapeutics股票价格,Nurix Therapeutics股票交易,Nurix Therapeutics股票购买,Nurix Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nurix Therapeutics(NRIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nurix Therapeutics(NRIX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}